The name for this is relapsed/refractory multiple myeloma (RRMM). When you have multiple myeloma, it's common for the cancer to come back after treatment and being in remission. This is called a ...

3 This deep dive into the relapse experience revealed insights about how people with multiple myeloma make treatment decisions when faced with disease recurrence and offered perspectives on managing ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

When Mateo Mejia Saldarriaga, MD, first started seeing multiple myeloma (MM) patients as a medical student in his native Colombia 10 years ago, he was intrigued by the multifaceted nature of this ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...